<DOC>
	<DOC>NCT00538681</DOC>
	<brief_summary>This study is intended for patients with advanced, not amenable to surgery, or metastatic lung cancer who have not received any prior chemotherapy. The study will be conducted in 2 parts: - Part 1 is intended to evaluate safety of pemetrexed + cisplatin + enzastaurin combination chemotherapy - Part 2 whose main objective is to compare the efficacy of pemetrexed + cisplatin + enzastaurin versus pemetrexed + cisplatin + placebo. Patients to be included in Part 2 are those with Nonsquamous NSCLC.</brief_summary>
	<brief_title>Study for Patients With Advanced, Not Amenable to Surgery, or Metastatic Lung Cancer Comparing Treatment With Pemetrexed + Cisplatin + Enzastaurin Versus Pemetrexed + Cisplatin + Placebo</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>diagnosis of advanced nonsmall cell lung cancer (NSCLC) not amenable to curative treatment. Patients enrolling in Part 2 of the study must have the above stated diagnosis of NSCLC that is also of nonsquamous histology. no prior systemic therapies (chemotherapy, etc.)or pleurodesis with chemotherapy for this disease prior radiotherapy is allowed but must be completed at least 2 weeks before study enrollment and patient must be recovered from the acute toxic effects have a good performance status patient must sign an informed consent document patient had myocardial infarction occurring less than 6 months before inclusion, uncontrolled arrhythmia, symptomatic angina pectoris, or cardiac failure not controlled by medications patient is unable to swallow tablets patient is taking a certain medicine to control seizure activity, called "enzyme inducing antiepileptic drugs" and is not able to stop taking the medicine prior to enrolling in the study patient is unable to interrupt aspirin and/or other antiinflammatory agents patient is unwilling or unable to take vitamin supplementation (folic acid and vitamin B12) or medications to prevent side effects</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
</DOC>